Recently, insulin glargine injection and insulin glargine injection (prefilled pen) of Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH ) have been successfully shipped to Brazil by sea. This is the first delivery since Gan & Lee’s insulin glargine obtained the registration approval issued by Brazilian National Health Surveillance Agency (ANVISA), indicating a significant commercialization progress for Gan & Lee since its march into the Brazilian market.
Image: insulin glargine injection and prefilled pen of Gan & Lee export to Brazil
As the major overseas market for Gan & Lee’s sales in Latin America, Brazil is one of top 10 countries who have the highest rate of diabetes (about 7.6%). Diabetes and its complications are the fifth cause of death in brazil, affecting 2.5% of population. Of 19.5 million diabetes patients, 1.5 million are undiagnosed1. As one of the pioneers who have developed biopharmaceutical standards in South America, Brazil is known for being time-consuming, requiring complicated dossiers and facing rigorous reviews in biopharmaceutical registration. This shipment has indicated the competitiveness of Gan & Lee in the industry and the company's insulin products have further increased in the global market share
Since 2005, Gan & Lee has established global business networks in more than 20 countries and regions, and has developed cooperation with developed countries such as Europe and the United States in 2014. The global business of Gan & Lee is mainly divided into seven areas including North America, Europe, Asia Pacific, Latin American, Commonwealth of Independent States (CIS), Middle Eastern & Northern Africa (MENA) and Sub-Saharan Africa (SSA). Besides this commercialization in Brazil, the company has made great achievements in the whole Latin America.
In 2020, Gan & Lee’s insulin glargine injection and insulin glargine injection (prefilled pen) have obtained the registration certificate from ANVISA. In the same year, insulin glargine API has obtained the registration certificate issued by Argentinean National Administration of Drugs, Foods and Medical Devices (ANMAT), and has been exported to Argentina for the first time in August. Gan & Lee has established business relationship with many clients in Latin America, and plans to cover the whole area in the future. Gan & Lee is dedicated to providing insulin and supporting medical devices for diabetes patients worldwide.
About Gan & Lee
Gan & Lee successfully developed the first Chinese domestic biosynthetic human insulin. The company has five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin®), fast-acting aspart injection (Rapilin™), mixed protamine zinc lispro injection (25R) (Prandilin®25), aspart 30 injection (Rapilin™30), reusable insulin injection pen (GanleePen™), and disposable pen needle (GanleeFine™).
In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance Gan & Lee’s goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities to treat various forms of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.
1. Brazil Diabetes Devices Market - Growth, Trends & Forecast (2020 - 2025). Mordor Intelligence.